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Abstract: Our aim was to analyse (i) the presence of single nucleotide polymorphisms (SNPs) in
the JUN and FOS core promoters in patients with rheumatoid arthritis (RA), knee-osteoarthritis
(OA), and normal controls (NC); (ii) their functional influence on JUN/FOS transcription levels;
and (iii) their associations with the occurrence of RA or knee-OA. JUN and FOS promoter SNPs were
identified in an initial screening population using the Non-Isotopic RNase Cleavage Assay (NIRCA);
their functional influence was analysed using reporter gene assays. Genotyping was done in RA
(n = 298), knee-OA (n = 277), and NC (n = 484) samples. For replication, significant associations were
validated in a Finnish cohort (OA: n = 72, NC: n = 548). Initially, two SNPs were detected in the
JUN promoter and two additional SNPs in the FOS promoter in perfect linkage disequilibrium (LD).
JUN promoter SNP rs4647009 caused significant downregulation of reporter gene expression, whereas
reporter gene expression was significantly upregulated in the presence of the FOS promoter SNPs.
The homozygous genotype of FOS promoter SNPs showed an association with the susceptibility for
knee-OA (odds ratio (OR) 2.12, 95% confidence interval (CI) 1.2–3.7, p = 0.0086). This association
was successfully replicated in the Finnish Health 2000 study cohort (allelic OR 1.72, 95% CI 1.2–2.5,
p = 0.006). FOS Promoter variants may represent relevant susceptibility markers for knee-OA.
Int. J. Mol. Sci. 2019, 20, 1382; doi:10.3390/ijms20061382 www.mdpi.com/journal/ijms
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1. Introduction
Rheumatic diseases, e.g., rheumatoid arthritis (RA) and knee-osteoarthritis (OA), are characterized
by inflammation and destruction of multiple joints. In RA, activated synovial fibroblasts are a
major component of the synovial membrane and contribute to joint destruction by the secretion
of pro-inflammatory cytokines and tissue-degrading enzymes [1,2]. OA is characterized by progressive
destruction of articular cartilage and bone and dysregulation of synovial function [3,4]. The OA
synovial membrane (SM) is prone to inflammatory processes [5], although inflammation occurs to a
lower extent than in RA.
Transcription factor activator protein (AP-) 1, a homo- or heterodimer of proteins of the
JUN/FOS-proto-oncogene families including JUN, JUNB, JUND, and FOS, appears to be strongly
involved in pro-inflammatory and pro-destructive processes in patients with RA and OA [6–9].
AP-1 showed binding activity for its cognate recognition sites in the promoters of inflammation-related
cytokines and matrix-degrading enzymes [10]. Therefore, AP-1 represents one of the transcription
factors thought to be critically involved in the pathogenesis of arthritides [6,11]. In general the JUN and
FOS family genes can be classified as “immediate-early response” genes, as they are rapidly induced
by a variety of activating agents and, on the other hand, have a very short half-life (range of minutes
for both mRNA and protein) [12]. Therefore, they can be regarded as markers of recent cell activation,
with clearly different biological activities of individual JUN/FOS family members [7,13].
Recently, substantial progress has been made in the identification of genetic components for
RA and OA [14,15]. However, additional genetic susceptibility variants need to be identified to
better understand the genetics of these diseases. Among the reported genetic factors, several single
nucleotide polymorphisms (SNPs) in the promoters of functionally relevant genes have demonstrated
an association with the occurrence of the respective disease. For example, associations with RA were
reported for SNPs in the interleukin 1β (IL1B) promoter [16] and the heme oxygenase I promoter [17].
Additionally, functional sequence alterations in the promoters of growth/differentiation factor 5 and
ras homolog gene family member B have shown an association with OA [18,19]. To our knowledge,
no candidate association studies have been published concerning the distribution of SNPs or mutations
in the JUN and FOS promoters of RA and OA patients.
Therefore, the aim of this study was to analyse SNPs in the core promoters of the proto-oncogenes
JUN, JUNB, JUND, and FOS in patients with rheumatic diseases, to investigate their functional
relevance, and to assess potential associations between these SNPs and the occurrence of RA or
knee-OA. To focus on the most relevant SNPs, a stepwise SNP selection protocol was performed:
(i) Selection of polymorphic SNPs in the initial screening population, (ii) filtering for SNPs with
functional effects, (iii) selection of SNPs associated with OA or RA in the discovery cohort, and (iv)
replication analysis in an independent, second case control cohort.
2. Results
2.1. Initial SNP Analysis in Rheumatoid Arthritis, Knee-Osteoarthritis, and NC Samples
In this study, SNPs in the JUN and FOS promoters with a functional relevance for their expression
levels in RA or OA should have been identified. Thus, the occurrence of SNPs in the JUN and FOS
family gene core promoters (i.e., up to 2 kb upstream of the start codon) were initially analysed in
DNA isolated from blood or SM samples of RA, knee-OA (n = 10 each), and NC (n = 5) patients using
NIRCA. Only major allele variants were detected for SNPs in the promoters of JUNB and JUND. In the
JUN promoter, 1 SNP was detected at position -1676 (C/G, major allele: C; rs4647001, position given
in regard to the start codon) in 1 RA sample and another SNP at position -617/-618 (insertion CA;
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major allele: Without insertion; rs4647009) in 2 RA samples. In the FOS promoter, 2 SNPs were detected
at positions -135 (A/T; major allele: A; rs2239615) and -60 (T/C, major allele: T; rs7101). Both were in
perfect LD the initial screening population. All SNPs were contained in dbSNP 130 [20].
2.2. Functional Analyses
To address the potential functional relevance of the identified SNPs, reporter gene assays were
performed following transfection of K4IM human fibroblasts, HeLa human epithelial cells, and NIH3T3
murine fibroblasts with reporter constructs. The occurrence of SNP rs4647001 in the JUN promoter did
not influence reporter gene expression with or without stimulation with 10 ng/ml phorbol-12-myristate
13-acetate (PMA; for 8 h; data available upon request). Regarding insertion rs4647009 (i.e., the minor
allele) of the JUN promoter, significant modulation of reporter gene expression was detected in K4IM
fibroblasts 1 and 2 d following transfection either with (downregulation by approx. 85%, p = 0.001
for 1 d, approx. 75%, p = 0.05 for 2 d) or without PMA stimulation (downregulation by approx. 70%,
p = 0.002 for 1 d, p = 0.05 for 2 d), as compared to the major allele (i.e., without insertion; Figure 1a,b).
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triplicates; mean ± standard error of the ean (SEM)). Firefly luciferase expression levels were
normalized to renilla luciferase expression levels in the respective samples (transfection and normalization
control). Results are presented as relative values (in %) related to the expression level in the presence of
the major allele at the respective time point (a,c). For better comparison, relative values related
to the expression level in the presence of the major allele in unstimulated cells at 1 d are also
given (b,d). ** p ≤ 0.005, * p ≤ 0.05 compared to the major allele. For JUN, the major allele is
the rs4647009-deletion (minor allele: Insertion CA), for FOS, the major allele refers to the combination
of rs7101-T and rs2239615-T.
Reporter gene expression was also differentially affected by alleles containing both SNPs in the
FOS promoter (rs2239615, rs7101): Compared to the major alleles, reporter gene expression in K4IM
cells was significantly upregulated in the simultaneous presence of both minor alleles. Without PMA
stimulation, reporter gene expression was upregulated by approximately 70% and 105% at 1 d and
2 d (p = 0.05 each), respectively. In the presence of PMA, 1 d after transfection an upregulation by
100% could be detected (p = 0.05), whereas reporter gene expression did not significantly differ among
major and minor alleles at 2 d (Figure 1c). In the latter case, however, expression levels were strongly
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upregulated (by approx. 235%, p = 0.05) in comparison to the major allele in unstimulated K4IM cells
at 1 d (Figure 1d). Absolute values of the respective experiments are presented in the Supplementary
Materials (Figure S1a,b).
Roughly comparable results have been obtained using HeLa and NIH3T3 cells. SNP rs4647009
caused a significant downregulation of the JUN promoter-dependent reporter gene expression without
(HeLa: >95%, p = 0.05 at both time points; NIH3T3: approx. 80% at both time points, P=0.04 for 1 d,
p = 0.05 for 2 d) or with PMA stimulation (HeLa: >95%, p = 0.05; NIH3T3: Approx. 80%, p = 0.04 at
both time points each) (Figure 2a and Figure S2). FOS promoter SNPs rs2239615 and rs7101 resulted in
a considerably upregulated reporter gene expression in both the absence (HeLa: >380%, p = 0.05 for 1
d, >200% for 2 d; NIH3T3: ≥10-fold at both time points, p = 0.04 for 1 d, p = 0.05 for 2 d) and presence
of PMA (HeLa: >130%, p = 0.04 for 1 d, >65% for 2 d; NIH3T3: ≥10-fold at both time points, p = 0.04
for 1 d, p = 0.05 for 2 d) (Figure 2c and Figure S2). Absolute values of the respective HeLa experiments
are presented in Figure S1c,d.
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2.3. Allelic Distribution of Polymorphisms and Statistical Analysis within the German Cohort
To analyse the allelic distribution of the identified SNPs, genotyping was performed in
RA (n = 298), kne -OA (n = 277), and NC ( = 484) DNA samples by single base exte sion
and matrix-assisted laser desorption/ionization—time of flight (MALDI-TOF) multiplex analysis.
Functional variants in the FOS promoter (rs2239615, rs7101) and JUN promoter (rs4647009) were found
to be frequent in the studied German Caucasian populations of RA cases, knee-OA cases, and NC
(Table 1). Frequencies of functional variants in NC were found to be similar to those reported for
Caucasian populations in dbSNP 130.
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The promoter variant rs4647009 in JUN was not significantly associated with either RA or OA
(Table 1). Promoter variants rs2239615 and rs7101 in FOS were found to be in perfect LD (r2 = 1.0;
D’ = 1.0), the minor allele of rs2239615 (T) corresponding to the minor allele of rs7101 (C). Consequently,
results of association analysis were similar for rs2239615 and rs7101 and are indicated hereafter as
results for rs2239615/rs7101. There was no statistically significant difference in the distribution of
rs2239615/rs7101 alleles between RA cases and NC (Table 1). In contrast, there was a significant
correlation of the minor allele of rs2239615/rs7101 with the susceptibility for knee-OA, carriage of the
homozygous minor genotype presenting a risk (Table 1). This association was reflected by the observation
of rs2239615/rs7101 not being in Hardy–Weinberg equilibrium (HWE) in OA cases, but showing
accordance with HWE in controls. In a recessive model, the OR for susceptibility to knee-OA was
approximately doubled for carriers of the homozygous minor allele rs2239615/rs7101 (Table 1).
Table 1. Association analysis of rs4647009 in JUN and rs2239615/rs7101 in FOS with RA and knee-OA.
Genotype counts are shown in percent (numbers). Due to the observed perfect LD between rs2239615
and rs7101, results of both SNPs are the same with allele rs7101-C corresponding to rs2239615-A, OR:
Odds ratio for the minor allele, Rs4647009 is an insertion (“CA”)/deletion (“−“) polymorphism.
Variable NC Cohort RA Cohort OA Cohort
rs4647009
(CA/CA) 0% (0) 0% (0) 0.4% (1)
(CA/−) 11.0% (53) 11.6% (34) 9.7% (27)
(−/−) 89.0% (427) 88.4% (260) 89.9% (249)
HWE p-value 0.2 0.29 0.78
Allelic OR (95% CI) / 1.05 (0.7–1.6) 0.95 (0.6–1.5)
Allelic OR p-value / 0.84 0.82
rs7101
Homozygous Minor (C/C) 5.0% (24) 5.1% (15) 10.1% (28)
Heterozygous (C/T) 35.1% (167) 40.3% (119) 29.2% (81)
Homozygous Major (T/T) 59.9% (285) 54.6% (161) 60.6% (168)
HWE p-value 0.98 0.24 0.0006
Allelic OR (95% CI) / 1.16 (0.9–1.5) 1.13 (0.9–1.4)
Allelic OR p-value / 0.23 0.35
Minor Recessive OR (95% CI) / 1.01 (0.5–2.0) 2.12 (1.2–3.7)
Minor Recessive OR p-value / 0.99 0.0086
2.4. Replication of the Genetic Association within the Finnish Cohort
For independent replication of the association of rs2239615/rs7101 with knee-OA, the distribution
of rs7101 was analysed in the Finnish Health 2000 study cohort. In line with the German cohort,
the minor allele of rs7101 was significantly associated in an additive model with the risk for knee-OA
in the Finnish cohort (OR 1.72, 95% CI 1.2–2.5, p = 0.006) (Table 2). The OR for carriers of at least one
minor allele was 2.0 (95% CI 1.2–3.3, p = 0.004).
Table 2. Association analysis of rs2239615/rs7101 in FOS with OA in the replication cohort.
Variable NC Cohort OA Cohort
Homozygous Minor (C/C) 17 4
Heterozygous (C/T) 184 35
Homozygous Major (T/T) 347 33
HWE p-value 0.26 0.23
allelic OR (95% CI) / 1.72 (1.2–2.5)
allelic OR p-value / 0.0058
Minor Recessive OR (95% CI) / 1.84 (0.6–5.6)
Minor Recessive OR p-value / 0.29
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2.5. Meta-Analysis of the German and Finnish Studies
In order to increase the power of the analysis and to further investigate the mode of inheritance,
we performed a fixed effect meta-analysis of the German and Finnish knee-OA studies (Figure 3).
Using an additive model, we found an allelic OR of 1.2 (95% CI 1.01–1.5, p = 0.037) with some
evidence for heterogeneity (p = 0.06). However, under a recessive model we found an OR of the
homozygous minor allele of 2.1 (95% CI 1.25–3.42, p = 0.004) with no evidence of heterogeneity
between studies (p = 0.82).
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3. Discussion
Progressive destruction of articular cartilage and bone and enduring dysregulation of normal
cellular behaviour in the SM are common features of different arthritides such as RA and
OA [2–5]. Many key proteins involved in their pro-inflammatory/pro-destructive properties,
e.g., chemokines/cytoki es an matrix-degrading enzymes, are transcriptionally regulated by AP-1
and its subunits JUN, JUNB, JUND, and FOS [6–9,21,22]. Based on the reasonable assumption that JUN
and FOS family proteins influence the development/progression of rheumatic diseases [6,11,23,24],
the distribution of fu ctionally relevant SNPs in the promoters of these proto-oncogenes and their
potential association with RA or knee-OA were analysed.
Various SNPs in the promoters of disease-relevant genes have shown an association with the
occurrence of RA [16,17] or OA [18,19]. However, to our k owledge, our study is the first candidate
gene association study c vering the allelic distribution of SNPs in the core region of the JUN and FOS
family promoters of RA and OA patients.
In the present study, association of two functionally relevant SNPs in the human FOS promoter
(rs2239615/rs7101; appearing in perfect LD) with the occurrence of knee-OA was demonstrated. Both
minor alleles normally occur with an allelic frequency of 26–30% (Supplementary Materials Table S1),
thus representing the SNPs with t e highest minor allele frequency (MAF) in this promoter region [20].
The other six know SNPs in the first 2 kb of t e hu an FOS promoter had considerably lower MAFs
(0.6–7%) [20] and were not detected in the initial SNP screening i OA and RA patients. Regarding
the promoters of all analyse genes, 60 SNPs were fou d in dbSNP, for 16 of which MAF had been
reported. T e ower to observe SNPs withi the initial screening population was 80% for SNPs with a
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reported MAF >3.2% (13 SNPs in dbSNP) and 99.5% for SNPs with a reported MAF >10% (11 SNPs in
dbSNP). Only four of the SNPs reported in dbSNP were identified in our study. This may be related to
differences in allele frequencies among Caucasian subpopulations, as described elsewhere [25].
In comparison to the major alleles, the minor alleles of SNPs rs2239615 and rs7101 modulated
promoter efficiency in reporter experiments by a marked upregulation of promoter-dependent gene
expression in different cell types including human and murine fibroblasts, both with and without
stimulation. After 2 d, no difference could be detected between the major and the minor FOS promoter
alleles in PMA-stimulated K4IM human fibroblasts, which may be ascribed to the high absolute
expression level reached. This indicated that the occurrence of these SNPs led to an enhanced activation
of the FOS promoter, possibly resulting in an overexpression of FOS proteins compared to long-term
stimulated cells carrying the major allele. Consequently, there may be a general increase in AP1 complex
formation [25,26] or a shift in the composition of the respective AP1 complexes [27]. To our knowledge,
evidence for the functional relevance of the aforementioned SNPs in the promoters of JUN/FOS family
genes was demonstrated for the first time in this study, emphasizing the potential importance of
promoter SNPs in key genes for disease pathogenesis. Using DNase I hypersensitivity data from the
ENCODE project [28], both SNPs appear to be located within open chromatin regions. Chromatin
immunoprecipitation data from the ENCODE project further showed that transcription factors serum
response factor (SRF), 300 kDa E1A-binding protein (EP300), TATA box binding protein-associated
factor (TAF) 1, hairy/enhancer of split-related with YRPW motif (HEY) 1, JUND, and POU domain
class 2 transcription factor 2 (POU2F2) bound within the region of the two SNPs. Accordingly, it is likely
that differential allelic binding of these or other transcription factors may contribute to differential
allelic expression of FOS. To our knowledge, cis regulation of FOS by rs2239615/rs7101 has not been
described before. However, effects of SNPs on cis regulatory elements outside the core promoter
(i.e., 800 kb distant from rs2239615/rs7101) have been described by Myers et al. (rs2591089, rs2543359,
rs935340) [29]. Therefore, the present study adds new and potentially relevant information concerning
the genetic regulation of FOS.
Allele distribution analysis in 298 RA and 277 knee-OA patients, as well as 484 NC individuals,
revealed that the minor alleles of both FOS promoter SNPs were significantly associated with the risk
for OA. Within this population, an individual’s homozygote for the minor allele occurred two times
more frequently in knee-OA than in RA or NC (10.1% vs. 5.1%), resulting in a significantly higher OR
(2.12) in OA patients (p = 0.0086). The enhanced frequency of the identified FOS promoter SNP alleles
in knee-OA patients, in combination with the identified potential functional effects, suggests that
SNPs rs2239615 and rs7101 may indeed enhance susceptibility for knee-OA. In this context, the major
allele seems to mediate a protective influence possibly due to a more limited expression of FOS,
even following stimulation. In contrast, the minor allele seems to upregulate FOS expression, even in a
quiescent status, possibly resulting in an enhanced expression of disease-mediating genes [1,30].
Replication of the association was performed in a Finnish cohort in a total of 620 individuals.
Although the number of OA individuals was smaller than that of the German study (i.e., 72 cases),
definition of the two cohorts showed many similarities. Of note, the OA phenotype within the Finnish
cohort was based on a clinical diagnosis similar to the definition of the OA phenotype in the original
German study group. This allowed factors such as pain to be included in the phenotype, in addition
to purely radiological phenotypes, which may have been lacking clinically important factors of the
disease. Analysis of the Finnish cohort also revealed the minor allele of rs7101 to be significantly
related to the risk of developing OA. Meta-analysis of both studies provided supporting evidence for
an association, suggesting a recessive mode of inheritance. As co-variates varied between cases and
controls, we performed additional analyses to address this issue. In the German group, a female-only
analysis showed increased effect size of the homo minor genotype (OR = 2.55, 95% CI 1.2–5.8, p = 0.019).
Within the smaller group of males, we found an OR = 1.6, 95% CI 0.6-4.0, p = 0.398). This effect size did
not differ significantly from that of females (p = 0.77), indicating no evidence of subgroup heterogeneity.
Similarly, results were highly comparable when excluding (Table 2) or including the co-variates age
Int. J. Mol. Sci. 2019, 20, 1382 8 of 13
and gender in the association analysis of the Finnish study (minor allele OR = 1.80, 95% CI 1.2–2.7,
p = 0.005). Thus, the detected promoter SNPs may have contributed to FOS-related disease progression
and joint destruction in OA in an age- and gender-independent fashion [24].
However, it has to be emphasized that the relatively small number of analysed individuals
represents a limitation of this study, even though OR and P values, as well as the successful
replication, suggest a relationship between the FOS promoter SNPs and the occurrence of OA. Recently,
genome-wide association studies (GWAS) for OA have been reported [15]. Associations with variants
in FOS were not reported among the top-hits of these GWAS. One explanation may be that our findings
could be characteristic for a yet undefined specific subgroup of knee-OA enriched in both the German
and the Finnish cohort. Future studies should further address this observation.
Due to the limited power of the study, a putative association of SNPs in the JUN family core
promoters with the RA or OA status could not be completely excluded, although variant rs4647009
in JUN was not associated with RA or OA in our study. Interestingly, there was differential allelic
modulation of promoter activity by this SNP and there were indications for a potential NF-κB binding
site in this region, as shown using the sTRAP method [31] (Figure S3). It remains to be investigated in
future studies, whether or not a genetic effect also exists for the JUN family promoter SNPs.
4. Materials and Methods
4.1. Patients and Tissue Samples
Within the German cohort, whole blood samples were collected from patients with RA
(n = 298) and OA (n = 277) in the Departments of Orthopedics and Internal Medicine III/Division
of Rheumatology and Osteology (Jena University Hospital) during routine blood withdrawal.
Blood samples from normal control (NC) donors (n = 484) were collected by the Institutes of Transfusion
Medicine (University Hospitals Jena and Leipzig) during standard blood donation. The health
status was controlled by hemogram, blood pressure measurements, individual medical history,
and determination of virus parameters. If DNA was not immediately isolated, blood samples were
stored at −20 ◦C.
Informed consent was obtained from all patients and donors before blood sampling.
The experiments were carried out in accordance with the relevant guidelines and regulations. The study
was approved by the Ethics Committee of the Jena University Hospital in accordance with the
Declaration of Helsinki. RA and OA patients were classified according to the respective criteria
of the American College of Rheumatology [32,33] valid within the sample assessment period. Clinical
characteristics of patients/donors are presented in the Supplementary Materials (Table S2). In all
patients, the disease reached a level requiring joint replacement surgery (advanced joint destruction
as assessed by radiography; categorized by the same team of clinicians), thus reflecting roughly
comparable disease stages in OA patients. For the analyses, exclusively OA patients with knee joint
involvement were selected. All RA patients showed several affected joints, mostly including the knees.
Replication of genetic associations was done in a Finnish cohort. This sample set was a subset
(Genmets) of the Finnish Health 2000 study cohort consisting of 2173 individuals, of which 2118 passed
the quality control after genotyping [34]. From the cohort of 2118 genotyped individuals, 75 individuals
were clinically diagnosed by a physician as having OA in one or two knee joints, did not have previous
meniscus or ligament injury, and did not have sero-positive, sero-negative, or unknown RA status.
In addition, 893 potential control individuals without OA, sero-positive, sero-negative, or unknown
RA status were identified. In order to closer match the replication cohort to the initial discovery cohort,
control and/or OA individuals who used NSAIDs, inhaled corticosteroids, had elevated levels of
rheumatoid factor (RF > 30 IU/mL), or used systemic corticosteroids were excluded, resulting in 72
knee-OA and 548 control individuals in the final replication cohort (Table S3). However, results were
virtually the same when all individuals were included (Table S4). Caucasian origin of the samples in
both cohorts was validated by self-disclosure and analysis of principal components of the genetic data.
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4.2. DNA Preparation
In the German cohort, genomic DNA was prepared from 1059 whole blood samples. Extraction
of DNA was performed using QIAamp DNA blood Mini kits or the Qiagen BioRobot EZ1 Workstation
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA concentrations were
determined using the Nanodrop ND-1000 system (PeqLab, Erlangen, Germany).
4.3. Conventional PCR
Conventional PCR was performed as previously described [35]. Core promoter sequences of
the JUN (1736 bases upstream of the start codon; divided into 2 overlapping PCR fragments),
JUNB (1831 bases; 2 fragments), JUND (1629 bases; 2 fragments), and FOS (2008 bases; 4 fragments)
were amplified using sequence-specific primers. The primers contained binding sites for the restriction
enzymes Eco RI or Bam HI (cloning into the vector pUC 19 for subsequent NIRCA analyses), and Hind
III or Not I (cloning into the vector pUBT-luc [36] for functional analyses), respectively. The protocols
for all amplified sequences are presented in the Supplement (Tables S5 and S6). Product specificity
was confirmed by agarose gel electrophoresis and fluorescent cycle sequencing.
4.4. Cloning of DNA Fragments
DNA fragments of each analysed sequence were cloned either as wild-type control for non-isotopic
RNase cleavage assay-based mutation analyses or for functional promoter analyses using reporter gene
constructs. Therefore, the amplified DNA sequences (restricted using Eco RI and Bam HI or Hind III and
Not I; New England Biolabs, Frankfurt/Main, Germany) were cloned by a standard ligation protocol
into the vectors pUC19 (Invitrogen, Darmstadt, Germany) or pUBT-luc (containing the reporter gene
firefly luciferase) [36].
4.5. Non-Isotopic RNase Cleavage Assay
For initial SNP verification in RA and OA samples, the highly sensitive non-isotopic RNase
cleavage assay (NIRCA) was applied using the MutationScreener kit (Ambion, Austin, TX, USA).
The assay was performed as previously described [37].
4.6. Functional Analyses
Endotoxin-free pUBT-luc plasmids (reporter gene: firefly luciferase) [36] containing wild-type or
SNP-containing sections of the JUN and FOS promoters were transfected into 1.5 × 105 K4IM human
fibroblasts, HeLa human epithelial cells, or NIH-3T3 murine embryonic fibroblasts per well (cultured
in DMEM + 10% FCS, 25 mM HEPES, 100 U/mL penicillin, 100 mg/mL streptomycin, 2.5 mg/mL
gentamicin; 6-well plates) using Polyfect (Qiagen) or X-tremeGENE 9 (Roche, Rotkreuz, Switzerland)
transfection reagents (determined in biological duplicates or triplicates). NIH3T3 cells were transfected
using 1000 ng pUBT-luc per well. Based on dose response experiments in which 100, 500, or 1000 ng
pUBT-luc were transfected into K4IM cells for 24 h (Figure S4), 500 ng pUBT-luc per well were applied
for subsequent transfections of K4IM and HeLa cells. As an internal transfection/normalization control,
the vector pRL-CMV (containing renilla luciferase; 10 ng/well) [38] was co-transfected. One and two
days after transfection, cells were lysed with passive lysis buffer (Promega), either without stimulation
or following 8 h stimulation with 10 ng/mL PMA. Firefly luciferase reporter gene expression was
assessed via luminescence emission measurements using the dual luciferase assay system (Promega),
normalized to renilla luciferase expression, and given as relative luciferase activity (RLA; i.e., firefly
relative light units (RLU) divided by Renilla RLU) or in percent of the respective control. In all cases
and at each time point, enzymatic activities of firefly and renilla luciferase were clearly detectable
as represented in the absolute RLA values (Figure 2 and Figure S1). Data of functional analyses are
presented as means ± standard error of the mean (SEM). The Mann–Whitney U test was applied to
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analyse differences between luciferase expression levels. Significant differences were accepted for
p ≤ 0.05.
4.7. Genotyping and Statistical Analysis
Genotyping of the German cohort was performed in RA (n = 298), knee-OA (n = 277), and NC
(n = 484) DNA samples by single base extension and MALDI-TOF multiplex analysis applying the
GenoLink system (Bruker Daltonics, Bremen, Germany). Primers and cycling conditions are shown in
the Supplementary Materials (Table S7). For the design of genotyping primers, the software Calcdalton
was used [39]. Reaction conditions were essentially the same as those described before [40]. Based on
allelic frequencies reported in dbSNP 130 [20], there was more than 80% power to detect allelic
differences of 4% and 7% for JUN and FOS SNPs, respectively [41]. Genotypes in controls were in
Hardy–Weinberg equilibrium. The average genotyping call rate was >99%. Frequencies of alleles
and genotypes were compared between cases and controls applying standard chi-square statistics or
Fisher’s exact test, as appropriate. Heterozygous genotypes of FOS −60/−135 (rs7101/rs2239615)
of knee-OA samples were independently validated by sequencing using independent PCR primers.
These independent PCR primers also allowed sequencing of the PCR primer binding sites of the
primers used for SNP identification and genotyping, thereby excluding genotyping errors due to
interfering polymorphisms at primer binding sites.
To replicate SNPs found to be significantly associated with the German discovery cohort,
an independent study of Finnish origin was used. Genotyping of the Finnish sample was done
using the Illumina HumanHap 610k array (Illumina, San Diego, CA, USA). For quality filtering,
individuals with a genotyping success rate of less than 95%, atypical genomic heterozygosity, gender
discrepancies, or relatedness with another individual were excluded from the study (nexcluded = 55).
Furthermore, valid markers had to achieve genotyping success rates of at least 95%, a minor allele
frequency (MAF) of at least 1% and accordance with Hardy–Weinberg equilibrium at the p-value
cut-off 1 × 10−6 or more, which was observed for 555,388 SNPs. Variant rs7101 fulfilled all quality
criteria mentioned, hence, no proxy was required for the replication analysis in the Finnish sample.
ENCODE-transcription factor data are available for public use within the UCSC genome browser.
They were created by the Myers Lab at the HudsonAlpha Institute for Biotechnology and by
the laboratories of Michael Snyder, Mark Gerstein, and Sherman Weissman at Yale University;
Peggy Farnham at UC Davis; and Kevin Struhl at Harvard. ENCODE digital DNase I hypersensitivity
clusters were made available for public use through the UCSC genome browser by the UW ENCODE
group [28].
p-Values for accordance with Hardy–Weinberg equilibrium, and association analysis (dominant,
recessive, allelic) were calculated by applying chi-square statistics or Fisher’s exact test, whenever
appropriate. Association analysis including the co-variates gender and age was done using PLINK [42].
For fixed-effects meta-analysis of association studies, Mantel–Haenszel methodology was applied,
as implemented in package rmeta 2.16, using R 2.15.0. Within this framework, combinability of the
cohorts was analysed with Woolf’s test for heterogeneity. For comparison of the OR of subgroups,
a test was performed as previously described [43].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/6/
1382/s1.
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AP-1 activator protein 1
CI confidence interval
EP300 300 kDa E1A-binding protein
FOS v-Fos FBJ murine osteosarcoma viral oncogene homolog
GWAS genome-wide association studies
HEY1 hairy/enhancer of split-related with YRPW motif 1
IL1B interleukin 1β




MAF minor allele frequency
MALDI-TOF matrix-assisted laser desorption/ionization—time of flight
NC normal controls




POU2F2 POU domain class 2 transcription factor 2
RA rheumatoid arthritis
RLA relative luciferase activity
RLU relative light units
SEM standard error of the mean
SM synovial membrane
SNP single nucleotide polymorphism
SRF serum response factor
TAF1 TATA box binding protein-associated factor 1
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